BIOREACT

Company Overview

BioReact is a B2B SaaS company pioneering the future of bioprocess optimization by leveraging advanced AI/ML algorithms to identify optimal conditions for cell growth, maximizing product yield, and improved scale-up efficiency. Our cutting-edge platform offers seamless data management and visualization along with AI powered process optimization. BioReact allows scientists to reduce development timelines and costs when bringing innovations from R&D to market while empowering stakeholders with data-driven decisions.

Problem or Market Opportunity

BioReact's market and commercialization strategy focus on targeted segmentation within the biotechnology industry. Leveraging advanced AI/ML algorithms, our B2B SaaS platform optimizes bioprocesses, maximizing product yield and scale-up efficiency. Through inbound and outbound marketing initiatives, strategic partnerships, and a customer-centric approach, we aim to penetrate biotech companies, emphasizing reduced development timelines and costs. Our tiered pricing strategy aligns with diverse customer needs, ensuring scalability and accessibility. With a commitment to exceptional customer success and support, BioReact is poised to lead the future of bioprocess optimization, empowering scientists with data-driven decisions from R&D to market.

Technical & Competitive Advantage

BioReact's technical edge lies in our ability to harness customer data to continually enhance our AI/ML algorithms, driving personalized recommendations and predictive insights. By analyzing real-time data from bioprocess experiments, we empower customers to optimize their next experiments, maximize yields, and minimize risks. This customer-centric approach not only sets us apart from competitors but also ensures ongoing innovation and value delivery.

Regulatory Strategy & Intellectual Property

BioReact operates in the R&D realm, thus exempt from FDA clearance requirements. Our focus on bioprocess optimization doesn't necessitate stringent regulatory approvals. Regarding intellectual property, our software platform and proprietary data are safeguarded as trade secrets. This ensures our competitive advantage, enabling us to innovate freely while protecting valuable assets.

Key Milestones

Q/YYYY	Objective	Milestone Description
Q4 2023	Prototype Build & Pilots	Build out BioReact software functionality and acquire pilot users.
Q3 2024	V1 Launch	Public release and transition pilot and waitlist users to paying users.
Q4 2024	Scale-Up Tool Launch	Upsell scale-up tool for scientists to accelerate R&D to manufacturing timelines

Capitalization History

Year	Grant or Equity Type	Description	Amount
2024	Seed	Seed Round Closing Soon	$750K

Current Round, Terms, and Use of Proceeds

BioReact will allocate proceeds towards hiring developers to enhance the platform's capabilities and investing in showcasing BioReact at scientific tradeshows and conferences to expand customer base and drive growth.

Key Team Members and Advisors

Mitchell Castetter | Founder and CSO

Mitchell has 7 years of life science and biotech experience in sales. Mitchell has sold over $10M of life science capital equipment and reagents to companies ranging from COVID vaccine manufacturers to synthetic biology laboratories.

Joanna Lipinski, PhD | Co-Founder and CTO

Joanna is an accomplished senior leader in biotechnology with over 20 years of industry expierience in biotech and software development. Joanna possesses expertise in assembling and leading diverse computational teams, and has consistently demonstrated her strategic prowess by setting direction and executing complex projects in informatics, data science, software engineering, and bioinformatics.

Andrew Chiappetta P.Eng | Co-Founder and CSO

Andrew possesses a professional background that spans over 10 years in vaccine manufacturing and synthetic biology companies. During his career, Andrew has held multiple positions in CMC Management, Process Validation, Life Cycle Management, and Process Development. Andrew earned a Bachelor's degree in Chemical Engineering from Queen's University in 2013, a Master's of Biotechnology degree from the University of Toronto, and is a licensed Professional Engineer.